264 Antibody-Drug Conjugates in Pipeline!!!!

Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. Billions of dollars are spent on the chemotherapy treatments annually. The ongoing research on this therapy will replace the chemotherapeutics treatments in the near future thereby reducing its toxic side effects. Different Biotechnology companies and Pharma Companies are collaborating in all area of ADCs like linker technology, antibody production and conjugation process. There are total 264 ADCs in pipeline and two are marketed.

Around 253 ADCs in Oncologydsad

Antibody-Drug Conjugates are getting researched mostly for cancers. Cancer being the highest research area, there are 253 ADCs currently in pipeline. There are other companies which is also researching the ADC for different therapeutic areas like dermatology, immunology, women’s health, gastrointestinal and ophthalmology.

Four Potential ADCs in Phase III Pipeline

Companies are trying its already marketed ADC for different combinations and fofffr different indications like Roche, Seattle Genetics conducting total 9 trials on their ADCs trastzumab emantisine and Brentuximab Vedotin. There are two new ADCs AstraZeneca’s Moxetumomab Pasudotox and Pfizer’s Inotuzumab Ozogamicin for Relapsed/ Refractory Hairy Cell Leukemia and Acute Lymphoblastic Leukemia respectively.

DelveInsight’s Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. The Report has covered the 264 Antibody-drug conjugates profile which gives core information of the targets, mechanism of action, development partner, Technology partner, monoclonal antibody used, linker used and cytotoxic drug with the descriptive information of the technologies. The Report also provides the assessment of the company’s undergone collaborations for technology and monoclonal antibody and also gives insights over the pre-clinical and clinical data. The Report has also assessed the ADCs on geographical distribution based on the country and region.

Pre-Launch Offer!!


We are giving a limited period offer of USD 500 off on Antibody-Drug Conjugate Global Market and Pipeline Outlook, 2015.


Single-User License Site License Global License
USD 3500 USD 7000 USD 10500

Ask for Sample Pages now!!!

For Sample Pages, please write to us at info@delveinsight.com

For more information about the company visit DelveInsight website